Page 231 - Haematologica April 2020

Fractures and survival in MM
16. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures corre- late with reduced survival in patients with malignant bone disease. Cancer. 2007;110 (8):1860-1867.
17. Sonmez M, Akagun T, Topbas M, et al. Effect of pathologic fractures on survival in multiple myeloma patients: a case control study. J Exp Clin Cancer Res. 2008;27:11.
18. McIlroy G, Mytton J, Evison F, et al. Increased fracture risk in plasma cell dyscrasias is associated with poorer overall survival. Br J Haematol. 2017;179(1):61-65.
19. Thorsteinsdottir S, Dickman PW, Landgren O, et al. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population- based study. Haematologica. 2018;103(9): e412-e415.
20. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in mul- tiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122-1128.
21. Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the gen- eral population: Increased incidence, older patients, and longer survival. Eur J Haematol. 2018 Apr 20. [Epub ahead of print]
22. Turesson I, Linet MS, Bjorkholm M, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malig- nancies in Sweden 1964-2003. Int J Cancer. 2007;121(10):2260-2266.
23. R: A language and environment for statisti- cal computing. [computer program]. Vienna, Austria: R Foundation for
Statistical Computing; 2018.
24. Gleiss A, Oberbauer R, Heinze G. An
diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematologica. 2018;103(3):506-
unjustified benefit: immortal time bias in
the analysis of time-dependent events. 513.
Transpl Int. 2018;31(2):125-130.
25. Kristinsson SY, Tang M, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood. 2010;116
(15):2651-2655.
26. Goyal G, Rajkumar SV, Lacy MQ, et al.
Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diag- nosed multiple myeloma. Leukemia. 2019;33(5):1273-1277.
27. Sigurdardottir EE, Turesson I, Lund SH, et al. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma. JAMA Oncol. 2015;1 (2):168-174.
28. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ, 3rd. Population- based study of survival after osteoporotic fractures. Am J Epidemiol. 1993;137(9): 1001-1005.
29. Katsoulis M, Benetou V, Karapetyan T, et al. Excess mortality after hip fracture in eld- erly persons from Europe and the USA: the CHANCES project. J Intern Med. 2017;281 (3):300-310.
30. Ray R, Clement ND, Aitken SA, McQueen MM, Court-Brown CM, Ralston SH. High mortality in younger patients with major osteoporotic fractures. Osteoporos Int. 2017;28(3):1047-1052.
31. Blimark CH, Turesson I, Genell A, et al. Outcome and survival of myeloma patients
32. von Metzler I, Krebbel H, Hecht M, et al. Bortezomib inhibits human osteoclastoge- nesis. Leukemia. 2007;21(9):2025-2034.
33. Lund T, Soe K, Abildgaard N, et al. First-line treatment with bortezomib rapidly stimu- lates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast prolif- eration and differentiation in vitro. Eur J Haematol. 2010;85(4):290-299.
34. Breitkreutz I, Raab MS, Vallet S, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia. 2008;22(10):1925-1932.
35. Bolzoni M, Storti P, Bonomini S, et al. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myelo- ma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Exp Hematol. 2013;41(4):387-397.
36. Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Bisphosphonates in multiple myeloma: an updated network meta-analy- sis. Cochrane Database Syst Rev. 2017;12:CD003188.
37. Therneau T, Crowson C, Atkinson E. Using time dependent covariates and time dependent coefficients in the cox model. 2019; http://cran.r-project.org/web/pack- ages/survival/vignettes/timedep.pdf. Accessed March 29.
haematologica | 2020; 105(4)
1073